SciSparc (SPRC) Competitors $1.80 -0.01 (-0.55%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.77 -0.03 (-1.67%) As of 09/15/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SPRC vs. SHPH, CNSP, SLXN, ENTO, DRMA, BDRX, GLTO, ARTL, RDHL, and INDPShould you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Shuttle Pharmaceuticals (SHPH), CNS Pharmaceuticals (CNSP), Silexion Therapeutics (SLXN), Entero Therapeutics (ENTO), Dermata Therapeutics (DRMA), Biodexa Pharmaceuticals (BDRX), Galecto (GLTO), Artelo Biosciences (ARTL), Redhill Biopharma (RDHL), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical products" industry. SciSparc vs. Its Competitors Shuttle Pharmaceuticals CNS Pharmaceuticals Silexion Therapeutics Entero Therapeutics Dermata Therapeutics Biodexa Pharmaceuticals Galecto Artelo Biosciences Redhill Biopharma Indaptus Therapeutics Shuttle Pharmaceuticals (NASDAQ:SHPH) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability. Is SHPH or SPRC more profitable? SciSparc's return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Shuttle PharmaceuticalsN/A -772.76% -347.06% SciSparc N/A N/A N/A Do insiders & institutionals hold more shares of SHPH or SPRC? 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher valuation & earnings, SHPH or SPRC? SciSparc has higher revenue and earnings than Shuttle Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioShuttle PharmaceuticalsN/AN/A-$9.15M-$4.15-0.84SciSparc$1.31M0.73-$6.28MN/AN/A Does the media favor SHPH or SPRC? In the previous week, SciSparc had 2 more articles in the media than Shuttle Pharmaceuticals. MarketBeat recorded 4 mentions for SciSparc and 2 mentions for Shuttle Pharmaceuticals. Shuttle Pharmaceuticals' average media sentiment score of 0.97 beat SciSparc's score of 0.47 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Shuttle Pharmaceuticals Positive SciSparc Neutral Which has more volatility & risk, SHPH or SPRC? Shuttle Pharmaceuticals has a beta of -1.08, indicating that its stock price is 208% less volatile than the S&P 500. Comparatively, SciSparc has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. SummarySciSparc beats Shuttle Pharmaceuticals on 7 of the 9 factors compared between the two stocks. Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRC vs. The Competition Export to ExcelMetricSciSparcMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$970K$2.56B$5.79B$10.18BDividend YieldN/A57.23%5.73%4.61%P/E RatioN/A23.2874.8626.39Price / Sales0.73692.88543.67125.97Price / CashN/A27.5625.8129.91Price / Book0.105.4013.256.28Net Income-$6.28M$32.95M$3.29B$270.38M7 Day PerformanceN/A-0.53%0.07%1.89%1 Month Performance-60.09%4.23%4.60%6.01%1 Year Performance-72.49%-2.81%72.95%25.26% SciSparc Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRCSciSparc0.2942 of 5 stars$1.80-0.6%N/A-71.4%$970K$1.31M0.004Analyst UpgradeSHPHShuttle Pharmaceuticals1.2944 of 5 stars$3.50+4.5%N/A-91.8%$3.75MN/A-0.845Short Interest ↓Gap DownCNSPCNS Pharmaceuticals1.77 of 5 stars$6.54+2.3%$300.00+4,490.7%-89.7%$3.73MN/A0.005News CoverageAnalyst UpgradeShort Interest ↑Gap UpSLXNSilexion Therapeutics2.7504 of 5 stars$5.06-28.7%$75.00+1,382.2%-97.4%$3.70MN/A0.00N/AENTOEntero TherapeuticsN/A$2.32-11.8%N/A+242.9%$3.69MN/A0.009Positive NewsShort Interest ↓DRMADermata Therapeutics2.4958 of 5 stars$5.19-1.3%$10.00+92.7%-65.6%$3.53MN/A-0.328Negative NewsBDRXBiodexa Pharmaceuticals0.5559 of 5 stars$5.61+5.5%N/AN/A$3.48M$470K0.0020Short Interest ↓GLTOGalecto3.4184 of 5 stars$2.58-16.5%$10.00+287.6%-78.1%$3.41MN/A-0.2040Positive NewsShort Interest ↓Gap DownHigh Trading VolumeARTLArtelo Biosciences3.3584 of 5 stars$4.68+2.9%$24.00+412.8%-25.8%$3.28MN/A-0.255Short Interest ↓RDHLRedhill BiopharmaN/A$1.42-1.4%N/A-86.4%$3.26M$8.04M0.00210Short Interest ↑INDPIndaptus Therapeutics3.3621 of 5 stars$2.69-7.6%$238.00+8,747.6%-94.6%$2.99MN/A-0.076Short Interest ↓Gap Down Related Companies and Tools Related Companies SHPH Alternatives CNSP Alternatives SLXN Alternatives ENTO Alternatives DRMA Alternatives BDRX Alternatives GLTO Alternatives ARTL Alternatives RDHL Alternatives INDP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRC) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRC Stock Alerts